Skip to content

A randomized, double-blind controlled clinical study of human umbilical cord mesenchymal stem cells (UC-MSC) delaying renal function progression in patients with chronic kidney disease (CKD3, Stage 4)

A randomized, double-blind controlled clinical study of human umbilical cord mesenchymal stem cells (UC-MSC) delaying renal function progression in patients with chronic kidney disease (CKD3, Stage 4)

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071983
Enrollment
Unknown
Registered
2023-05-31
Start date
2021-04-13
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Chronic Kidney Disease(CKD3?4 )

Interventions

Control group:Regular medication + placebo
Experimental group:Regular medication+HMUMSC

Sponsors

Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Patients with clinical diagnosis of chronic kidney disease (CKD) and stage 3 and stage 4 (GFR 15-60 ml/min) of CKD (American Kidney Disease Foundation stage) (2)Agree to sign the informed consent form at the same time by means of participation of the pilot group (3)Age between 18-65 years old

Exclusion criteria

Exclusion criteria: (1)Patients who are taking immunosuppressants or have been taking them within a month (2)Patients with a 30% increase in creatinine in the past 3 months and who are about to undergo dialysis (3)Suffering from severe heart, respiratory insufficiency, viral hepatitis, and sexually transmitted diseases (4)Hypersensitivity to stem cells themselves or stem cell-related media (5)Patients with recent bacterial, viral, or fungal infections (6)Have a history of tumors or are currently suffering from tumor conditions (7)Pregnant or breastfeeding (8)Have participated in drug-related clinical trials in the past two months (9)Any form of substance abuse, mental illness, and other conditions that researchers believe may affect the effectiveness of the test or the patient's physical health

Design outcomes

Primary

MeasureTime frame
German Federal Republic (GFR);

Secondary

MeasureTime frame
Incidence of serious adverse events;Immunoglobulin A;Immunoglobulin G;Immunoglobulin M;Complement C3;Complement C4;Type C reactive protein;interleukin-6;Peripheral hemolymocyte subsets;Urine protein;Urine RBC;24-hour urine protei;Urine albumin/creatinine;Electrolytes;Hemoglobin;Albumin;Heart ultrasound;Carotid ultrasound;Amino-terminal pro brain natriuretic peptide;1, 25dihydroxyvitamin D3;

Countries

China

Contacts

Public ContactGang Xu

Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology

xugang@tjh.tjmu.edu.cn+86 135 0718 1312

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026